FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein in formula (I) R1 is selected from hydrogen, amino or from a group consisting of C1-3 alkyl and C3-6 cycloalkyl, and said group is optionally substituted with 1 R; R2 is selected from a group consisting of C1-3 alkyl, C3-6 cycloalkyl and phenyl, and said group is optionally substituted with 1 R; R3 denotes hydrogen; optionally, R2 and R3 are bonded to form 5-member ring; each of R4 and R5 is independently selected from hydrogen, halogen or is C1-3 alkyl; L is selected from a single bond, -CH2-; R is selected from CN, OH, or C1-6 alkyl, optionally substituted with 1, 2 or 3 R'; R' is F. Invention also relates to individual compounds, to pharmaceutical compositions, to the use of the compound, to the use of the pharmaceutical composition, to a pharmaceutical combination.
EFFECT: technical result is obtaining novel compounds of formula (I), having the properties of a TGF-βRI inhibitor.
19 cl, 7 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| BENZOXEPIN PI3 INHIBITORS AND METHODS FOR USING THEM | 2010 |
|
RU2557658C2 |
| COMPOUNDS OF PYRIDAZINAMIDE AND THEIR USE AS SYNTHETIC SYNECKINASIS INHIBITORS (SYK) | 2013 |
|
RU2627661C2 |
| USE OF 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | 2017 |
|
RU2759380C2 |
| mTOR KINASE INHIBITORS FOR ONCOLOGICAL INDICATIONS AND DISEASES METABOLICALLY BOUND TO mTOR/PI3K/AKT | 2009 |
|
RU2546658C2 |
| PHOSPHODIESTERASE 10 MODULATORS | 2012 |
|
RU2567396C1 |
| AMINOTRIAZOLOPYRIDINES AND USING THEM AS KINASE INHIBITORS | 2009 |
|
RU2552642C2 |
| OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | 2014 |
|
RU2674983C1 |
| INHIBITOR CONTAINING BICYCLIC DERIVATIVE, METHOD OF PREPARATION AND USE THEREOF | 2020 |
|
RU2820948C2 |
| INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | 2014 |
|
RU2666532C2 |
| PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS AN MTOR/PI3K INHIBITOR | 2015 |
|
RU2658912C1 |
